shutterstock_294492536_esb_professional
ESB Professional / Shutterstock.com
22 July 2021AmericasAlex Baldwin

PTAB grants inter partes review of China’s firm’s Alzheimer’s patent

The US Patent Trial and Appeal Board (PTAB) has given the go-ahead for an inter partes  review of a Chinese pharma company’s US patent related to a treatment for Alzheimer’s.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Genetics
14 August 2019   Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.
Americas
23 August 2016   AstraZeneca and Eli Lilly have received US Food and Drug Administration fast track designation for the development of a treatment for Alzheimer’s.

More on this story

Genetics
14 August 2019   Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.
Americas
23 August 2016   AstraZeneca and Eli Lilly have received US Food and Drug Administration fast track designation for the development of a treatment for Alzheimer’s.

More on this story

Genetics
14 August 2019   Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.
Americas
23 August 2016   AstraZeneca and Eli Lilly have received US Food and Drug Administration fast track designation for the development of a treatment for Alzheimer’s.